REGN

Regeneron Pharmaceuticals Inc. is a biotechnology company that discovers, develops and commercializes prescription medicines, primarily using its proprietary VelocImmune antibody‑discovery platform and the Regeneron Genetics Center to generate biologic and small‑molecule therapies. Its portfolio includes blockbuster products such as EYLEA for retinal diseases, Dupixent (co‑developed with Sanofi) for atopic dermatitis, asthma and other inflammatory conditions, and Libtayo for certain cancers, with additional candidates spanning ophthalmology, immunology, oncology and cardiovascular areas. Operating within the specialty biopharma sector, Regeneron combines direct U.S. sales for key drugs with profit‑sharing and licensing partnerships that extend its reach globally. The firm is recognized as a top‑tier biotech firm, noted for its innovative platforms, strong pipeline of late‑stage candidates and a collaborative business model that leverages both in‑house commercialization and strategic alliances.